James Lankford (R-OK)
Ensuring Access to Lower-Cost Medicines for Seniors Act
A Republican bill with 2 Democratic cosponsors · See all 2 cosponsors
Last activity — Read twice and referred to the Committee on Finance.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, titled the "Ensuring Access to Lower-Cost Medicines for Seniors Act," seeks to amend the Social Security Act regarding Medicare drug plans. It requires prescription drug plan sponsors and Medicare Advantage organizations to include certain generic drugs and biosimilar biological products on their formularies if they have a lower wholesale acquisition cost than the reference drug. The legislation also mandates specific cost-sharing tiers to ensure these lower-cost options are affordable for seniors. Additionally, it prohibits certain restrictive access limits on these required drugs. These rules would apply to plan years beginning on or after January 1, 2028.
Yes· 3 of 9
- Scored +9
Would people over 65 be better off under this?
The bill directly reduces prescription drug costs for seniors on Medicare through mandatory inclusion of lower-cost drugs and lower cost-sharing tiers.
- Scored +9
Would retired people be better off under this?
The bill lowers medication costs through specific tiering requirements for Medicare drug plans.
- Scored +8
Does this lower the price of prescription medicines?
The bill requires Medicare plans to include lower-cost generic and biosimilar drugs on their formularies and mandates lower cost-sharing tiers for them.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Mandatory Inclusion of Lower-Cost Medicines: Plan sponsors must include generic drugs and biosimilar biological products on their formularies if the wholesale acquisition cost is less than the reference drug. This ensures that cheaper alternatives are available to those on Medicare plans (Section 2(a)(i)(I-II)).
-
Protections Against Access Restrictions: The bill prohibits plans from imposing limits on access—such as prior authorization, utilization management, or step therapy—that are more restrictive than those applied to the more expensive reference drug (Section s 2(a)(iii)).
-
Reduced Out-of-Pocket Costs through Tiering: Plans must include a cost-sharing tier for generics and biosimilars that features either no cost-sharing or a copayment that is at least $20 lower than the lowest branded drug tier (Section 2(a)(K)(i)(II)).
-
Lower Specialty Tier Costs: If a plan has a specialty tier, it must include a second specialty tier specifically for generics and biosimilars that has a coinsurance requirement at least 5 percentage points lower than any other specialty tier (Section 2(a)(K)(ii)(I-II)).
Potential Negative Impacts for People
- Deductible Restrictions: The bill limits a plan's ability to approve benefit designs that have a deductible applicable to generic or biosimilar drugs unless that deductible also applies to all other covered drugs on the formulary (Section 2(a)(K)(iv)(II)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would retired people be better off under this? — The bill lowers medication costs through specific tiering requirements for Medicare drug plans. Would people over 65 be better off under this? — The bill directly reduces prescription drug costs for seniors on Medicare through mandatory inclusion of lower-cost drugs and lower cost-sharing tiers. Would households on low incomes be better off under this? — Lower prescription drug costs provide financial relief to low-income seniors. Would middle-income households be better off under this? — The bill helps middle-income seniors reduce their healthcare-related out-of-pocket expenses.
- Healthcare
- Does this lower the price of prescription medicines? — The bill requires Medicare plans to include lower-cost generic and biosimilar drugs on their formularies and mandates lower cost-sharing tiers for them. Does this make health care easier to get in general? — By lowering out-of-pocket costs for essential medications, the bill makes healthcare more affordable for seniors. Does this put more money into Medicare, the health coverage for people over 65? — The bill indirectly influences Medicare spending by mandating lower cost-sharing tiers for generic and biosimilar drugs.
- Social Issues And Justice
- Does this strengthen Social Security? — The bill improves the value of Medicare benefits by reducing out-of-pocket costs for medications.
- Economy And Finance
- Is this likely to grow the economy? — By mandating the inclusion of lower-cost generics and biosimilars, the bill may slightly encourage market competition.
- 8/6/2026
- 1 Cosponsor added.
- 4/16/2026
- Read twice and referred to the Committee on Finance.
- 1 Cosponsor added.
- Introduced in Senate
Michael BennetDemocrat · Colorado
Maggie HassanDemocrat · New Hampshire